Choosing between Jardiance and Farxiga can feel overwhelming, especially when both medications offer similar benefits for blood sugar control, heart failure, and kidney protection. As two of the most prescribed SGLT2 inhibitors, they’re often compared side by side by patients and providers alike. But despite their similarities, there are subtle differences that might make one a better fit depending on your specific health goals.
This guide breaks down how Jardiance and Farxiga stack up, from their FDA approvals and heart failure data to practical concerns like daily routines and side effects. Whether you’re newly diagnosed with type 2 diabetes or looking to add another layer of protection against heart or kidney disease, this comparison can help you make an informed decision with your care team.
What is Jardiance?
Jardiance, manufactured by Boehringer Ingelheim, is a prescription medication that received FDA approval in August 2014 for the treatment of type 2 diabetes. Since then, it has become a commonly prescribed option for managing the condition. Its active ingredient, empagliflozin, inhibits the sodium-glucose co-transporter 2 (SGLT-2) in the kidneys, which leads to increased glucose elimination through urine. Although initially approved to help control blood sugar in type 2 diabetes, Jardiance has demonstrated additional benefits for cardiovascular and kidney health. Clinical studies have shown it can lower the risk of cardiovascular death in adults with type 2 diabetes and established heart disease. It is also indicated to reduce the risk of hospitalization for heart failure, including in individuals without diabetes.
What is Farxiga?
Farxiga, developed by AstraZeneca, is a prescription medication approved by the FDA in January 2014 for managing type 2 diabetes. Since its approval, it has become a widely used option for blood sugar control. The active ingredient, dapagliflozin, blocks the sodium-glucose co-transporter 2 (SGLT-2) in the kidneys, which increases glucose excretion through urine. While originally intended for type 2 diabetes management, Farxiga has also shown benefits for cardiovascular and renal health. Clinical trials have demonstrated that Farxiga can reduce the risk of hospitalization for heart failure and slow the progression of chronic kidney disease. It is also approved for use in patients with heart failure, both with reduced and preserved ejection fraction, even in the absence of diabetes.
How Do SGLT2 Inhibitors Like Jardiance and Farxiga Work?
SGLT2 stands for sodium-glucose co-transporter 2, a protein found in the kidneys that reabsorbs glucose from the urine back into the bloodstream. In other words, it recycles glucose that would otherwise be excreted, contributing to higher blood sugar levels. Jardiance and Farxiga, as SGLT2 inhibitors, block this protein, allowing more glucose to be expelled in the urine, which helps reduce blood glucose levels.
The SGLT2 protein also reabsorbs sodium along with glucose, so by inhibiting it, these medications promote the excretion of both glucose and sodium. This mild diuretic effect reduces blood volume, which can help lower blood pressure.
In addition to Jardiance and Farxiga, the SGLT2 inhibitor class includes Invokana (canagliflozin) and Steglatro (ertugliflozin). Some are also available in combination with metformin or DPP-4 inhibitors, such as saxagliptin, linagliptin, or sitagliptin, for patients requiring dual therapy. Although these drugs share a similar mechanism, their FDA-approved indications and supporting clinical data differ.
Jardiance vs Farxiga: Head-to-Head Comparison
Understanding the nuances between these two leading SGLT2 inhibitors can help tailor therapy based on comorbidities, clinical goals, and patient preferences. Here’s how they compare:
FDA Approvals and Primary Uses
Jardiance (empagliflozin)
- Approved in August 2014 for type 2 diabetes.
- Later gained FDA approval to reduce cardiovascular death in adults with type 2 diabetes and established heart disease.
- Now approved for heart failure (both HFrEF and HFpEF), making it one of the few agents with evidence in both types.
Farxiga (dapagliflozin)
- Approved in January 2014 for type 2 diabetes.
- Subsequently expanded to include heart failure (HFrEF and HFpEF) and chronic kidney disease (CKD), regardless of diabetes status, a key differentiator.
- Also studied for delaying kidney disease progression, supported by data from the DAPA-CKD trial.
Dosage and Formulation
- Jardiance: 10 mg or 25 mg once daily
- Farxiga: 5 mg or 10 mg once daily
Both are oral, once-daily tablets that can be taken with or without food. Starting doses are typically 10 mg, with upward titration as needed. Neither requires renal dose adjustment at initiation, though monitoring is recommended, especially in patients with reduced eGFR.
Efficacy in Heart Failure
Jardiance
- EMPEROR-Reduced and EMPEROR-Preserved trials support its use in both types of heart failure.
- Reduces the risk of cardiovascular death and hospitalization for heart failure.
Farxiga
- DAPA-HF and DELIVER trials confirm benefit in HFrEF and HFpEF, respectively.
- Also shown to slow CKD progression and reduce all-cause mortality in certain populations.
Both improve heart failure outcomes, but Farxiga has broader renal data. Jardiance may have a slight edge for cardiovascular death reduction, especially in diabetics with ASCVD.
Articles you may also be interested in
Side Effects and Safety
Common Reactions Tied to Urine Glucose Loss
Jardiance works by helping the kidneys flush excess glucose into the urine, but this mechanism can lead to predictable side effects, especially in the first few weeks:
- Dehydration
- Urinary tract infections (UTIs)
- Yeast infections (more common in women)
- Nasopharyngitis (a fancy term for the common cold)
Drink plenty of fluids, maintain good hygiene, and report any burning during urination or increased fatigue.
Rare But Serious Complications
Though uncommon, some side effects may require urgent medical attention:
- Diabetic ketoacidosis (DKA) – even if blood sugar is only mildly elevated
- Acute kidney injury (AKI) – due to volume loss or other risk factors
- Fournier’s gangrene – a rare but life-threatening soft tissue infection of the perineum
Know the Signs: Nausea, vomiting, abdominal pain, confusion, or signs of infection should prompt immediate care.
Who’s More Vulnerable?
Some groups are at increased risk of complications and may need closer monitoring:
- Adults 65 years or older
- Patients with chronic kidney disease (CKD)
- Anyone who is volume-depleted (e.g., on diuretics, has low oral intake, or recently had vomiting/diarrhea)
Follow-up is key: Regular labs and check-ins help minimize risk and keep treatment on track.
Farxiga and Jardiance in Daily Life
Both Farxiga and Jardiance are convenient, once-daily oral tablets with no food restrictions, which can be easily incorporated into almost any medication regimen and morning routine. Most people take these medications first thing in the morning to prevent nighttime urination.
Unlike insulin or other medications, missing a dose of Farxiga or Jardiance isn’t an emergency. However, you should do your best to take it every day to get the full effects. If you do miss a dose and remember later that day, you can safely take that missed dose. If you don’t remember until the following day, just skip that missed dose and resume your normal dosing schedule. Do not double up on missed doses.
Farxiga and Jardiance are also easy to travel with, as they do not require refrigeration. The prescription bottle can be placed in any travel bag, as long as it is kept at room temperature. Extremely hot temperatures may affect the medication. While traveling, stay hydrated because both medications increase urination, which can increase the risk of dehydration.
Switching between Jardiance and Farxiga
Do not take both Jardiance and Farxiga at the same time. If you and your doctor decide it is best to switch to another SGLT2 inhibitor, you can safely switch medications by taking the new SGLT2 inhibitor at least 24 hours after your last dose of your previous medication. An extended wash-out period is not required.
Farxiga vs Jardiance for Your Specific Health Goals
Want to Lower A1c?
Fortunately, both Jardiance and Farxiga are effective at managing type 2 diabetes, with similar A1c reductions of 0.5-1%. Both medications are dose-dependent, meaning the higher doses may provide slightly better A1c improvement compared to lower doses. SGLT2 inhibitors are not typically used as a 1st-line treatment option for type 2 diabetes, however. Metformin is well-established and considered a first-line therapy. SGLT2 inhibitors should be an add-on therapy for those with cardiovascular disease, heart failure, or kidney disease. Jardiance or Farxiga may occasionally be used alone if the A1c is at goal and you were not able to tolerate metformin in the past.
Worried About Heart Failure?
Both Jardiance and Farxiga are approved to treat heart failure, even in people without diabetes. They’ve been shown to reduce the risk of hospitalization for heart failure and slow disease progression. Jardiance is FDA-approved for heart failure with reduced or preserved ejection fraction (HFrEF and HFpEF), while Farxiga is approved for HFrEF and HFpEF as well. While both work similarly, some prescribers lean toward Jardiance in patients with preserved EF due to more robust data. If heart failure is a concern, either medication could be a strong add-on, even if blood sugar is well controlled.
Want Kidney Protection?
Jardiance and Farxiga have both been studied for their kidney benefits. Farxiga is FDA-approved to reduce the risk of kidney disease progression in people with chronic kidney disease (CKD), with or without diabetes. Jardiance has shown kidney benefits, too, though its kidney-specific approval is limited to patients with type 2 diabetes and CKD. Both can reduce albuminuria and slow down eGFR decline. If you’re managing CKD, especially with protein in the urine, Farxiga may have a slight edge, but both are used in clinical practice for kidney protection.
What If I Can’t Take Either?
If neither works, talk to your doctor about other options. There are newer diabetes medications, like GLP-1 receptor agonists or dual agonists like Mounjaro and Ozempic, that also support blood sugar, heart, and kidney health.
What to Expect in the First 30 Days
| Timeline | What You Might Notice | Tips & What to Do |
| Days 1–3 | Increased urination, mild thirst | This is normal. Your kidneys are excreting glucose and sodium. Drink water consistently. |
| Days 4–7 | Possible fatigue or lightheadedness | May be due to fluid loss or a slight drop in blood pressure. Stay hydrated and rise slowly from sitting. |
| Week 2 | Blood sugar may begin trending lower | Monitor your glucose if you have a home meter. Adjust carbs or insulin with provider input if needed. |
| Week 2–3 | Common side effects: mild yeast infection, UTI, or nasal stuffiness | Good hygiene helps. Report burning, itching, or discomfort. These are usually treatable. |
| Week 3–4 | Small drop in weight or blood pressure | Often a welcome benefit! Weight loss is modest and due to glucose and water loss. |
| End of Month | Feeling more stable on the medication | Time for a check-in: discuss with your doctor if you should stay on your current dose or increase it. |
Conclusion
Jardiance and Farxiga are more than just blood sugar medications. They are treatments that can support heart and kidney health, too. While the clinical differences between them are subtle, they can matter depending on your specific goals and medical history. Whether you’re looking for A1c reduction, heart failure support, or kidney protection, both are strong options with years of data to back them.
Work with your provider to decide which one aligns best with your priorities. And remember, managing chronic conditions isn’t about finding the “perfect” pill—it’s about choosing the right tool at the right time. If Jardiance or Farxiga isn’t quite right, you’ve still got other options worth exploring.
